JP2024517130A5 - - Google Patents

Info

Publication number
JP2024517130A5
JP2024517130A5 JP2023565138A JP2023565138A JP2024517130A5 JP 2024517130 A5 JP2024517130 A5 JP 2024517130A5 JP 2023565138 A JP2023565138 A JP 2023565138A JP 2023565138 A JP2023565138 A JP 2023565138A JP 2024517130 A5 JP2024517130 A5 JP 2024517130A5
Authority
JP
Japan
Prior art keywords
targeting agent
agent according
tumor
antibody
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565138A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517130A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/000243 external-priority patent/WO2022224041A1/en
Publication of JP2024517130A publication Critical patent/JP2024517130A/ja
Publication of JP2024517130A5 publication Critical patent/JP2024517130A5/ja
Pending legal-status Critical Current

Links

JP2023565138A 2021-04-22 2022-04-22 グリア芽腫を治療するための方法および組成物 Pending JP2024517130A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163178054P 2021-04-22 2021-04-22
US63/178,054 2021-04-22
PCT/IB2022/000243 WO2022224041A1 (en) 2021-04-22 2022-04-22 Methods and compositions for treating glioblastoma

Publications (2)

Publication Number Publication Date
JP2024517130A JP2024517130A (ja) 2024-04-19
JP2024517130A5 true JP2024517130A5 (https=) 2025-05-01

Family

ID=82594861

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565138A Pending JP2024517130A (ja) 2021-04-22 2022-04-22 グリア芽腫を治療するための方法および組成物

Country Status (5)

Country Link
US (1) US20240197784A1 (https=)
EP (1) EP4326775A1 (https=)
JP (1) JP2024517130A (https=)
IL (1) IL307842A (https=)
WO (1) WO2022224041A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116715773B (zh) * 2023-02-28 2024-03-01 星奕昂(上海)生物科技有限公司 一种靶向5t4的抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250071286A (ko) * 2016-01-10 2025-05-21 네오티엑스 테라퓨틱스 엘티디. 면역강화제에 의해 증진되는 초항원 매개된 암 면역요법
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
CA3139899A1 (en) * 2019-05-15 2020-11-19 Neotx Therapeutics Ltd. Cancer treatment

Similar Documents

Publication Publication Date Title
CN105492016B (zh) 脑信号蛋白-4d抑制分子与免疫调节治疗联用以抑制肿瘤生长和转移的应用
CN114929278A (zh) 抗ccr8抗体及其用途
JP6767362B2 (ja) リンパ球における阻害経路の中和
US9828432B2 (en) Cancer treatment and monitoring methods using OX40 agonists
JP2018514550A5 (https=)
JP2014531409A5 (https=)
JP7459058B2 (ja) Ｃｄ１３７／ｈｅｒ２二重特異性物質とｐｄ－１系阻害物質とを含む併用療法およびその使用法
JP2021523170A (ja) 癌の処置
CN113412130A (zh) 用于诊断和治疗癌症及其他疾病的对促肿瘤癌症相关成纤维细胞的识别和靶向
CN112004828B (zh) 头颈癌的治疗
WO2022247708A1 (en) Use of her2-targeting antibody-drug conjugate in treatment of her2-low expressing breast cancer
JP2024506550A5 (https=)
CN109863402A (zh) 基于β2-糖蛋白1水平的用巴维昔单抗治疗癌症的方法和其测定
AU2021250615A1 (en) Fully human anti-human CD22 chimeric antigen receptor and application thereof
JP2024517130A5 (https=)
US20220111047A1 (en) Formulations of antibodies that bind human cd137 and uses thereof
JP2025504020A (ja) Ｐｄ－１アゴニストであるプログラム細胞死タンパク質１に対する抗体
WO2019199896A9 (en) Agonist antibodies against human cd137 in cancer that express mhc i
JP2023530997A5 (https=)
TW202432585A (zh) 癌症新輔助治療的組合物及方法
WO2025239904A1 (en) Parkinson's disease therapy by developing a treg-mediated response specific to alpha-synuclein and diagnosis methods
WO2026082153A1 (zh) 抗Nectin-4抗体药物偶联物治疗肿瘤的用途
WO2023017149A1 (en) Thioredoxin 1 antibodies
WO2024149224A1 (zh) Ccr8抗体的应用
CN116997570A (zh) 用于治疗抗体介导的移植排斥的抗cd38抗体